Europe Allergy Immunotherapy Market Size, Share, and Growth Forecast 2026 - 2033

Europe allergy immunotherapy market size is expected to be valued at US$ 1.2 billion in 2026 and projected to reach US$ 1.9 billion by 2033, growing at a CAGR of 6.7% between 2026 and 2033. Rising allergic disease prevalence across Europe is the primary force behind this growth.

The European Academy of Allergy and Clinical Immunology reports allergic conditions affecting a large share of the European population. Growing physician preference for disease-modifying immunotherapy, expanding sublingual tablet adoption, and rising food allergy diagnoses among children continue to widen demand for immunotherapy across hospitals, specialty clinics, and home care settings throughout the region. Continued expansion of reimbursement coverage across several member states further reinforces this steady upward trajectory.

Market Growth Drivers

Rising Prevalence of Allergic Rhinitis and Asthma Across Europe

Allergic disease prevalence continues climbing steadily across Europe. The European Academy of Allergy and Clinical Immunology reports that allergic rhinitis affects a substantial share of the European population each year. The World Health Organization Regional Office for Europe notes that respiratory allergic conditions remain among the most common chronic diseases across the region. This growing patient base is prompting physicians to consider immunotherapy earlier in treatment protocols rather than relying solely on antihistamines. Longer pollen seasons linked to shifting climate patterns are also intensifying allergy symptom severity across many European countries.

Allergy specialists increasingly view immunotherapy as a long-term disease-modifying option rather than temporary symptom relief. This shift in clinical practice is expanding the addressable patient population for subcutaneous and sublingual immunotherapy products across the region. National allergy societies across Germany, France, and the United Kingdom continue publishing updated treatment guidelines reinforcing this trend. Growing referral volumes from primary care physicians to board-certified allergists further support this expanding treatment funnel.

Expanding Regulatory Approvals for Sublingual Immunotherapy Products

Regulatory approvals are broadening the immunotherapy treatment landscape across Europe. The European Medicines Agency has approved multiple sublingual immunotherapy tablets for grass, tree, and house dust mite allergies over the past decade. These tablet-based therapies offer patients a convenient, at-home alternative to traditional injection-based treatment. National health authorities across several member states have expanded reimbursement coverage for sublingual immunotherapy tablets in recent years.

Companies such as ALK-Abelló A/S and Stallergenes Greer continue advancing sublingual tablet platforms through the European regulatory pathway. This expanding menu of approved treatment options is encouraging allergists to prescribe immunotherapy more frequently across the region. Broader product availability also strengthens competitive positioning for manufacturers seeking to capture rising demand across multiple allergy types. Continued clinical trial investment should further expand this approved treatment landscape in coming years. Growing cross-border regulatory harmonization within the European Union should further simplify future product approvals.

Restraints - Lengthy Treatment Duration Limiting Patient Adherence

Allergy immunotherapy typically requires three to five years of continuous treatment to achieve lasting benefit. This extended commitment discourages many patients from completing their prescribed course. The European Academy of Allergy and Clinical Immunology has noted that patient dropout remains a persistent challenge within immunotherapy programs across the region.

Frequent clinic visits required for subcutaneous immunotherapy injections add further burden for working patients and parents managing pediatric treatment schedules. This adherence gap limits the overall clinical and commercial impact of immunotherapy, even as awareness of its long-term benefits grows across Europe. Reduced completion rates ultimately affect real-world treatment outcomes and future product utilization. Patients living in rural areas with limited specialist access face even greater difficulty maintaining consistent treatment schedules over multi-year courses.

Reimbursement Variability Across European Healthcare Systems

Allergy immunotherapy reimbursement varies considerably across different European healthcare systems. Each member state maintains its own national health insurance framework with distinct coverage criteria for immunotherapy products. This fragmented reimbursement landscape creates inconsistent patient access across the region. Patients in countries with limited public coverage often face substantial out-of-pocket costs for extended treatment courses lasting several years.

The European Federation of Allergy and Airways Diseases Patients' Associations has highlighted this access disparity as a persistent barrier to broader treatment adoption. Manufacturers must navigate distinct pricing and approval processes across multiple national markets simultaneously. This regulatory complexity increases administrative costs and slows market entry timelines for new immunotherapy products across the region.

Opportunities - Growing Adoption of Sublingual Immunotherapy Tablets in Home Care Settings

Sublingual immunotherapy tablets present a significant growth opportunity for market participants across Europe. These tablet-based treatments allow patients to self-administer therapy at home rather than visiting clinics for regular injections. This convenience factor is particularly appealing to time-constrained working adults and parents managing pediatric allergy treatment across the region. Companies such as HAL Allergy B.V. and LETI Pharma have expanded their sublingual tablet portfolios to capture this rising preference.

Telehealth-supported allergy consultations are also making it easier for physicians to monitor patients undergoing home-based sublingual treatment across rural and underserved areas. As more patients seek convenient alternatives to weekly injection visits, manufacturers that expand sublingual product lines and strengthen physician education programs stand to capture disproportionate growth. This shift toward home-based care aligns well with broader European healthcare trends favoring decentralized treatment delivery.

Expanding Oral Immunotherapy Access for Pediatric Food Allergy Patients

Food allergy treatment represents a fast-growing opportunity within the Europe immunotherapy market. The European Academy of Allergy and Clinical Immunology reports that food allergy prevalence among European children has risen substantially over the past two decades. This growing patient population is driving demand for oral immunotherapy treatments capable of desensitizing children to common food allergens. Growing parental awareness of oral immunotherapy as a treatment option, supported by pediatric allergist advocacy across the region, is expanding referral volumes to specialty clinics.

Companies that invest in pediatric-focused clinical trials and expand physician training programs can capture strong early demand within this expanding segment. Rising school and public awareness of food allergy management across European countries also supports sustained long-term growth potential for oral immunotherapy products throughout the region.

Therapy Type Analysis

Subcutaneous Immunotherapy (SCIT) held the leading position among therapy types, accounting for approximately 41% share of the market in 2026. This leadership reflects SCIT's long clinical track record and broad allergist familiarity across Europe. Subcutaneous injections allow physicians to treat multiple allergens simultaneously within a single treatment protocol, unlike single-allergen sublingual tablets. National allergy societies across Germany and France continue recognizing SCIT as a well-established, evidence-backed treatment option for allergic rhinitis and asthma.

Established reimbursement pathways for SCIT within many national health insurance systems also support continued physician preference. While Sublingual Immunotherapy is growing faster due to its home-administration convenience, SCIT's broader allergen coverage and established clinical infrastructure keep it the dominant therapy type through the near-term forecast period across the region. Widespread allergist training in SCIT protocols further reinforces this continued clinical preference.

Allergy Type Analysis

Allergic Rhinitis led the allergy type category, capturing an estimated 38% share of the market in 2026. This leadership stems from its position as the most commonly diagnosed allergic condition across Europe. The European Academy of Allergy and Clinical Immunology reports that allergic rhinitis affects a substantial share of the European population annually, driven by seasonal pollen exposure and indoor allergens such as dust mites.

Physicians frequently recommend immunotherapy for patients with moderate to severe allergic rhinitis symptoms that do not respond adequately to standard antihistamine therapy. Both subcutaneous and sublingual immunotherapy products are widely available and reimbursed for this indication across most member states. While Food Allergy treatment is growing rapidly, its smaller current base keeps Allergic Rhinitis the leading allergy type category through the forecast period. Rising diagnosis rates among younger patients should continue reinforcing this segment's broad demand base.

End User Analysis

Specialty Allergy Clinics represented the leading end user category, holding an estimated 46% share of the market in 2025. This dominance reflects the specialized expertise required for allergen testing, immunotherapy formulation, and ongoing patient monitoring. Board-certified allergists operating within dedicated clinics manage the majority of immunotherapy prescriptions across Europe. National medical associations maintain certification standards that support this concentrated referral pattern toward specialty practices. These clinics also maintain the infrastructure needed to manage rare anaphylactic reactions during in-office immunotherapy administration.

Home care is growing quickly as sublingual tablet adoption increases, Specialty Allergy Clinics retain leadership due to their central role in diagnosis, treatment initiation, and ongoing clinical oversight throughout the forecast period across the region. Growing clinic network expansion across suburban areas should further reinforce this segment's leadership position.

Germany Allergy Immunotherapy Market Size

Germany led the Europe allergy immunotherapy market, holding an estimated 28% share in 2025. This leadership reflects the country's extensive allergist network and strong health insurance-funded treatment access. The German Allergy and Asthma Association reports steady growth in immunotherapy prescriptions nationwide. Companies such as Bencard Allergie GmbH and ROXALL Medizin GmbH maintain significant domestic manufacturing and distribution presence.

Rising allergic rhinitis prevalence and strong physician awareness continue supporting demand. Statutory health insurance coverage also ensures broad patient access to routine and specialized immunotherapy treatment. Germany is expected to remain the region's largest market through the forecast period.

U.K. Allergy Immunotherapy Market Size

The United Kingdom is projected to register the fastest growth among Europe's major markets through 2033. Expanding National Health Service investment in specialty allergy referral pathways is a key growth catalyst. The National Health Service has increasingly prioritized immunotherapy access for patients with severe allergic rhinitis and venom allergy. This trend is creating substantial new treatment volume for specialty allergy clinics across the country.

Rising public awareness of immunotherapy as a long-term treatment option is also strengthening demand. Growing waiting list pressures continue pushing more diagnostic and treatment volume toward specialty allergy providers. The United Kingdom's growth trajectory positions it as an increasingly important market for manufacturer investment.

France Allergy Immunotherapy Market Size

France holds a significant share of the Europe allergy immunotherapy market. The country's allergist workforce continues expanding to meet rising patient demand. Companies such as Stallergenes Greer maintain extensive domestic manufacturing and distribution infrastructure. France's national health insurance system supports broad access to routine and specialized immunotherapy treatment. Growing demand for pollen and dust mite allergy treatment continues driving steady volume growth. Rising pediatric allergy diagnosis rates are also expanding referral volumes to specialty allergists. France should continue growing steadily alongside broader European market trends.

Italy Allergy Immunotherapy Market Size

Italy represents a steadily growing share of the Europe allergy immunotherapy market. Companies such as Lofarma S.p.A. maintain strong domestic production and distribution networks. Regional healthcare variation creates some difference in immunotherapy access across northern and southern Italy. Growing physician awareness of sublingual tablet options is gradually narrowing this access gap. Rising allergic rhinitis and food allergy diagnoses continue supporting demand nationwide. Italy's market should continue growing steadily through the forecast period.

Spain Allergy Immunotherapy Market Size

Spain contributes a meaningful share to the Europe allergy immunotherapy market. The country hosts several established immunotherapy manufacturers, including LETI Pharma, Laboratorios Inmunotek S.L., and Diater Laboratorio de Diagnóstico y Aplicaciones Terapéuticas S.A. This strong domestic manufacturing base supports steady product availability and innovation. Rising allergic rhinitis prevalence linked to Mediterranean pollen exposure continues driving demand. Spain's well-established immunotherapy research base should continue supporting steady market growth through the forecast period.

Europe allergy immunotherapy market remains moderately consolidated among established European manufacturers. Companies such as ALK-Abelló A/S, Stallergenes Greer, and HAL Allergy B.V. compete through broad allergen extract portfolios and established physician relationships. Smaller specialized firms including Anergis SA differentiate through novel immunotherapy delivery platforms.

Market leaders are investing heavily in clinical trials to expand approved indications across additional allergen types. Digital patient adherence tools and telehealth integration are emerging as differentiating strategies among competitive manufacturers. Strategic partnerships between manufacturers and specialty clinic networks are becoming increasingly common as companies seek to strengthen distribution across the fragmented European allergy care landscape. Growing investment in pediatric-focused product lines is also emerging as a key competitive differentiator.

Key Developments

• In June 2026, Stallergenes Greer announced that it would present new clinical evidence at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 in Istanbul, highlighting long-term outcomes of allergen immunotherapy (AIT).
• In December 2025, Allergy Therapeutics plc received German regulatory approval for Grassmuno, its short-course subcutaneous immunotherapy (SCIT) for grass pollen allergy. The approval enables the product's commercial launch in Germany, the company's largest market, and supports the transition to fully licensed allergen immunotherapies under Germany's Therapy Allergen Ordinance (TAV).